comparemela.com

Latest Breaking News On - Alex andrianopoulos - Page 1 : comparemela.com

A potentially deadly infection from a common fungus saw Paul Minuzzo s jaw surgically removed

A Queensland man was woken one night by a "ten out of ten pain". It was a fungal infection in his bone that led to his top jaw being surgically removed, and now he thinks it's coming back.

Vivodyne Announces $38 Million Seed Financing Led by Khosla Ventures to Develop Lab-Grown Human Organs

Vivodyne Announces $38 Million Seed Financing Led by Khosla Ventures to Develop Lab-Grown Human Organs
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Vivodyne Announces $38 Million Seed Financing Led by Khosla Ventures to Develop Lab-Grown Human Organs

Vivodyne, a biotech that discovers and develops more effective drugs by testing them on lab-grown human organs, today announced the close of $38 million in total seed financing, led by Khosla Ventures, with participation from Kairos Ventures, CS.

Kalamata and Peloponnese links to Melbourne promoted in Victorian parliament

Bone treatment startup raises $5 5 M in Series A financing

 E-Mail IMAGE: The image shows fractured femurs at three weeks post-fracture. Yellow and orange colors indicate higher density bone than purple and blue and the green arrows point towards the fracture site.. view more  Credit: Novosteo Inc. Novosteo Inc., a preclinical-stage biotechnology startup focused on the development of bone-targeted therapeutics, announced Thursday (February 4) the closing of a $5.5 million in Series A financing to advance its development of the first-ever targeted bone anabolic agent NOV004. The compound has shown promise in live animals in the acceleration of fracture healing when delivered systemically. NOV004 is unique in that it concentrates at the fracture site while avoiding accumulation in the rest of the body. Proceeds from the financing will be used to advance NOV004 into clinical development that will begin in the first half of 2021.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.